Posts made in July, 2017

Schooling impacts on the overactive bladder diagnosis in women

Vol. 43 (x): 2017 June 6.[Ahead of print]

doi: 10.1590/S1677-5538.IBJU.2016.0575


ORIGINAL ARTICLE

Larissa R. Ferreira 1, Monica O. Gameiro 2, Paulo R. Kawano 3, Hamilto A. Yamamoto 1, Rodrigo Guerra 3, Leonardo O. Reis 3, João L. Amaro 1
1 Departamento de Urologia, Faculdade de Medicina de Botucatu, Universidade Estadual Paulista, Botucatu, Brasil; 2 Serviço de Reabilitação Perineal, Faculdade de Medicina de Botucatu, Universidade Estadual de São Paulo, Botucatu, Brasil; 3 Faculdade de Medicina de Campinas, Pontifícia Universidade Católica de Campinas – PUC Campinas, Campinas, Brasil

ABSTRACT

Objective: To evaluate the overactive bladder (OAB) diagnosis using OAB-V8 and ICIQ-OAB questionnaires in women with different schooling and cultural levels.

Materials and Methods: Three hundred and eighty six healthy women answered a clinical questionnaire filling out information about schooling, demographic and gyne­cological data. The OAB-V8 and ICIQ-OAB questionnaires were used to evaluate OAB diagnosis and symptoms; and the QS-F questionnaire, to determine the sexual func­tion. All questionnaires were validated in Portuguese.

Results: The mean age was 37.3 years-old. Regarding to schooling level, 23.1% had concluded primary education; 65.8%, secondary school; and 11.1% had higher edu­cation. Considering the OAB-V8 (score ≥8), 51.8% of evaluated women had OAB di­agnosis. There was a positive linear correlation between the OAB-V8 and ICIQ-OAB questionnaires in its sections “a” (r=0.812, p<0.001) and “b” (r=759, p<0.001). There was a positive linear correlation between age and the amount of time used to answer the OAB-V8, ICIQ-OAB and QS-F questionnaires...

Read More

Lysozyme gene treatment in testosterone induced benign prostate hyperplasia rat model and comparasion of its’ effectiveness with botulinum toxin injection

Vol. 43 (x): 2017 June 6.[Ahead of print]

doi: 10.1590/S1677-5538.IBJU.2016.0677


ORIGINAL ARTICLE

Osman Ergün 1, Pınar Aslan Koşar 2, İbrahim Onaran 2, Hakan Darıcı 3, Alim Koşar 4
1 Department of Urology, Konya Training and Research Hospital, Konya, Turkey; 2 Department of Medical Biology and Genetic, Süleyman Demirel University, Isparta, Turkey; 3 Deparment of Histology and Embryology, Süleyman Demirel University, Isparta, Turkey; 4 Department of Urology, Süleyman Demirel University, Isparta, Turkey

ABSTRACT

Objectives: To compare the effects and histopathological changes of botulinum neurotoxin type A and lysozyme gene injections into prostate tissue within a testosterone induced benign prostate hyperplasia rat model.

Materials and Methods: 40 male Wistar rats were randomized into four Groups. Group-1: Control, Group-2: Testosterone replacement, Group-3: Testosterone+botulinum neurotoxin type A, Group-4: Testosterone+plazmid DNA/liposome complex.

Results: Estimated prostate volume of the testosterone injected Groups were higher than the control (p <0.05). Actual prostate weight of the testosterone injected Groups was higher than the control Group (p <0.05). Testosterone undecanoate increased the prostate weight by 39%. Botulinum neurotoxin type A treatment led to an estimated prostate volume and actual prostate weights decreased up to 32.5% in rats leading to prostate apoptosis. Lysozyme gene treatment led to an estimated prostate volume and actual prostate weights decrease up to 38.7%.

Conclusion: Lysozyme gene and botulinum neurotoxin type A treatments for prostate volume decreasing effect have been verified in the present study that could be anew modality of treatment in...

Read More

The Middle Term

Vol. 43 (4): 577-578, July – August, 2017

doi: 10.1590/S1677-5538.IBJU.2017.04.01


EDITORIAL in this Issue

Stênio de Cássio Zequi
Editor Associado, International Braz J Urol
Divisão de Urologia do A.C. Camargo Cancer Center
Fundação A. Prudente, São Paulo, Brasil

As it is been daily debated, the dilemmas on to treat or not to treat patients with localized prostate cancer are under the scope of the “Difference of opinion section”: Between two extremes: the radical whole gland treatments versus the active surveillance protocols, the “middle term”, probably will be arise from judicious and individualized patient selection. Using biomolecular markers, nomograms, modern magnetic resonance evaluations and the individual patient preferences and payment capacities, the urologists will be able to decide a personalized approach’s, varying from traditional whole gland therapies, passing by the emerging focal treatments until exclusive surveillance. Concomitantly, in the future, less patients will be overdiagnosed and overtreated. Our readers will be able the get their self “middle term decisions”, after reading the favorable arguments (Dell´Oglio and Sanchez Salas, from Paris) and contrary to treatment (Schulman and Polascyck, from North Carolina)…

[Read more]


Most of patients with localized prostate cancer will be treated in the future? | Opinion: Yes

Vol. 43 (4): 579-583, July – August, 2017

doi: 10.1590/S1677-5538.IBJU.2017.04.02


DIFFERENCE OF OPINION

Paolo Dell’Oglio 1,2, Rafael Sanchez-Salas 1
1 Department of Urology, Institut Mutualiste Montsouris, Paris, France; 2 Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy

Keywords: Prostatic Neoplasms; Patients; Epidemiology


INTRODUCTION

Localized prostate cancer (LPCa) is an heterogeneous disease extending from individuals who harbor indolent cancer, that are highly unlikely to develop metastases, to individuals with more aggressive disease, that have higher risk of metastatic burden. This would translates into different oncologic outcomes and have implications for disease management.

Once the diagnosis of LPCa is established, remains challenging to identify those patients who may benefit from delayed or immediate treatment. Several options exist, from active surveillance (AS) to the whole-gland treatments (1). However, the optimal one is still unclear. To date, the percentage distribution of treatment for LPCa is around 8.4% for observation, 13.1% for ablative therapies, 28.1% for external beam radiotherapy (RT), 1.6% for brachytherapy, 45% for radical prostatectomy (RP) and 3.7% for primary androgen deprivation therapy (2)…

[Read more]


Most of patients with localized prostate cancer will be treated in the future? | Opinion: No

Vol. 43 (4): 584-587, July – August, 2017

doi: 10.1590/S1677-5538.IBJU.2017.04.03


DIFFERENCE OF OPINION

Ariel A. Schulman 1, Thomas J. Polascik 1
1 Division of Urology, Duke University Medical Center, Durham, NC, USA

Keywords: Prostatic Neoplasms; Patients; Epidemiology


 

We are in the midst of a major shift in the diagnosis and management of localized prostate cancer. The prevailing approach of the 1980’s and 1990’s focused on widespread population-based prostate specific antigen (PSA) testing and curative-intent treatment for any detected cancer. The philosophical approach in the most recent decade is now defined by risk-adapted PSA screening, and integration of novel imaging techniques and biomarkers to increase the detection of clinically significant cancer. Concomitantly, we are witnessing the expanding utilization of active surveillance and partial ablation trategies to avoid overtreatment. We believe that continued development in each of these areas will continue to decrease the number of patients with localized disease treated with traditional whole gland surgery or radiation in the future…

[Read more]